ESR1 and neoplasm: For ESR1-positive/HER2-positive tumors the situation is different; HER2 mRNA has a more continuous distribution and the response to neoadjuvant trastuzumab/chemotherapy rises continuously with the amount of HER2 mRNA within the HER2-positive tumor group.